Top Analytics Companies in Dublin (87)

Strong Revenue Growth: Revenue has scaled to over $1.2B with continued double-digit quarterly increases and an outlook nearing $1.5B, indicating sustained momentum. Guidance increases reinforce the trajectory of ongoing top-line expansion.

Market Expansion: International revenue is growing faster than the overall business and now represents a significant share of total revenue, with customers across more than 100 countries. The customer base surpassing 205,000 underscores broader geographic reach and upmarket penetration.

Customer Loyalty & Retention: Net revenue retention remains above 100%, suggesting existing customers are expanding spend through cross-selling and wider platform adoption. Larger-account cohorts are growing rapidly, including rising counts of $50K+ and $1M+ ARR customers.

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.

Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.

Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.

Resilient & Sustainable Growth: Revenue continues to rise year over year, with recent quarters showing steady low–double-digit expansion and management guiding to continued growth in 2026. Feedback suggests the business is prioritizing balanced expansion over hypergrowth.

Cost & Operational Efficiency: Operating performance has improved, with GAAP losses narrowing and non-GAAP operating income and margins moving higher. Guidance points to a stronger exit margin by year-end 2026, indicating tighter cost control and operating leverage.

Diversified Customer Base: The company serves tens of thousands of customers across more than 100 countries, and the number of higher-ARR customers has increased. This breadth, alongside upmarket traction, supports ongoing expansion across segments.

Strong Market Position & Advantage: The company is widely recognized as a leader in GIS/location intelligence with entrenched adoption across mission‑critical government and enterprise use cases and independent analyst recognition. Ecosystem scale and longstanding dominance indicate a durable competitive moat.

Diversified Customer Base: The software serves hundreds of thousands of organizations across governments, cities, global enterprises, and universities in numerous industries worldwide. This breadth across sectors and geographies supports resilient demand.

Innovation-Driven Growth: The company consistently reinvests heavily in R&D and delivers frequent product updates and new capabilities across the ArcGIS platform, including cloud, real‑time analytics, and SDK enhancements. Ongoing launches and roadmap activity signal a sustained innovation engine.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.

Strong Revenue Growth: Company disclosures and third‑party signals indicate record 2025 revenue and continued customer additions, pointing to sustained momentum into early 2026. Multi‑year references to accelerating growth reinforce a continued top‑line expansion narrative.

Strong Market Position & Advantage: Independent analyst assessments repeatedly place the company among the Leaders, often at or near the top of recent EOR evaluations. Consistent leadership mentions across multiple years suggest durable competitive strength and commercial traction.

Innovation-Driven Growth: Product updates and recognition around the AI‑powered G‑P Gia and expanded platform capabilities are cited as differentiators supporting scale. Product adoption signals emphasize that continued releases and customer references would further validate a product‑led growth story.

Strong Revenue Growth: Primark is described as delivering rising sales and profitability across recent years, including increases in revenue and operating profit. Growth is linked to strong foot traffic, selective price increases, and improved digital touchpoints like website enhancements and click-and-collect.

Market Expansion: Primark is depicted as expanding its store footprint across multiple regions, including continued rollout in the US, growth in Central and Eastern Europe, and planned entry/expansion in the Middle East. New store openings are repeatedly positioned as a key contributor to overall sales growth.

Strong Market Position & Advantage: Primark is portrayed as holding a leading position in the UK apparel market with sustained market share strength supported by its value pricing and trend-led offering. High brand awareness and a large store network reinforce its competitive advantage in physical, value-oriented fashion retail.

Strong Market Position & Advantage: Independent outlets such as WIRED and Forbes Vetted highlight Balsam Hill among the best and most realistic artificial trees, reinforcing premium leadership. Company and trade communications consistently position Balsam Hill as a leading global retailer of high‑quality artificial trees, aligned with broad recognition in consumer press.

Market Expansion: Opened Balsam Hill Studio locations in Hawai‘i and added a dedicated Canada site, indicating geographic and channel expansion beyond pure DTC. Visibility via national holiday activations further extends reach and brand presence.

Strategic Partnerships: Secured the official global brand licensing partnership for GE holiday lighting starting in the 2026 season, expanding category and distribution opportunities. High‑profile holiday activations and collaborations reinforce premium positioning and awareness.